(Q40884177)

24 September 2017

1 reference

title

The search for new triazole antifungal agents (English)

1 reference

24 September 2017

Y Koltin

1

1 reference

PubMed ID

9667858

24 September 2017

C A Hitchcock

series ordinal

2

1 reference

24 September 2017

1 August 1997

1 reference

Current Opinion in Chemical Biology

24 September 2017

1 reference

24 September 2017

1

1 reference

24 September 2017

2

1 reference

24 September 2017

176-182

1 reference

Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980007-5

7 January 2021

Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980007-5

7 January 2021

Lipid formulations of amphotericin B: recent progress and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980007-5

7 January 2021

Amphotericin B: new life for an old drug

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980007-5

7 January 2021

Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980007-5

7 January 2021

Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980007-5

7 January 2021

Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980007-5

7 January 2021

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980007-5

7 January 2021

Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980007-5

7 January 2021

High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980007-5

7 January 2021

Itraconazole cyclodextrin solution: the role of in vitro susceptibility testing in predicting successful treatment of HIV-related fluconazole-resistant and fluconazole-susceptible oral candidosis

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980007-5

7 January 2021

Antifungal agents: chemotherapeutic targets and immunologic strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980007-5

7 January 2021

Resistance of Candida species to fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980007-5

7 January 2021

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980007-5

7 January 2021

In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980007-5

7 January 2021

Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980007-5

7 January 2021

In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980007-5

7 January 2021

Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980007-5

7 January 2021

In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980007-5

7 January 2021

Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980007-5

7 January 2021

A dose comparison study of a new triazole antifungal (D0870) in HIV-positive patients with oral candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980007-5

7 January 2021

10.1016/S1367-5931(97)80007-5

Identifiers

DOI

1 reference

24 September 2017

1 reference

PubMed ID

9667858